Search - tctmd.com

Displaying 421 - 440 of 909

Sort: Relevancy | Date

Presentation TCT 2018

DANCE: Two-Year Outcomes of Adventitial Dexamethasone Delivery During Femoropopliteal Revascularization

Presenter: Lindsay S. Machan, Craig M. Walker, Ehrin J. Armstrong

September 22, 2018

Presentation TCT 2018

CHIP in The Diabetic Patient: Special Considerations

Presenter: David J. Maron, Steven P. Marso, Cindy L. Grines

September 22, 2018

Presentation TCT 2018

Case #8: A Case of Revascularization Planning by FFRCT (From SYNTAX III)

Presenter: Nick Curzen, Robert D. Safian, Colin Berry, Pamela S. Douglas, Jonathon A. Leipsic, Hitoshi Matsuo, Erick Schampaert, Daniel I. Simon

September 22, 2018

Presentation TCT 2018

Complete Revascularization is the Missing Link to Improve Diabetic PCI Outcomes

Presenter: David J. Maron, Steven P. Marso, Konstantinos Dean Boudoulas

September 22, 2018

Presentation TCT 2018

When is PCI a Valid Alternative To Only Medical Therapy or CABG in the Diabetic Patient?

Presenter: David J. Maron, Steven P. Marso, Sripal Bangalore

September 22, 2018

Presentation TCT 2018

Medical Therapy for Whom and When: What is the Ceiling of Medical Therapy?

Presenter: David J. Maron, Steven P. Marso, Norman E. Lepor

September 22, 2018

Presentation TCT 2018

Comprehensive CV Risk Reduction Strategy in Diabetics

Presenter: David J. Maron, Steven P. Marso, Kurt Huber

September 22, 2018

Presentation TCT 2018

Is It Time to Move Beyond Angiography for Procedural Planning? DECISION

Presenter: Antonio Colombo, Jeffrey W. Moses, Gregg W. Stone

September 22, 2018

Presentation TCT 2018

Is It Time to Move Beyond Angiography for Procedural Planning? SYNTAX III

Presenter: Antonio Colombo, Jeffrey W. Moses, Antonio L. Bartorelli

September 22, 2018

Presentation TCT 2018

MVD Case Presentation With Heart Team Discussion, Case Introduction

Presenter: Antonio Colombo, Jeffrey W. Moses, Carlos Collet, Pablo Lamelas, John D. Puskas, Alfredo E. Rodriguez, Pieter C. Smits, Wilson Y. Szeto

September 22, 2018

Presentation TCT 2018

Hybrid Revascularization as an Alternative to PCI or CABG

Presenter: Antonio Colombo, Jeffrey W. Moses, John D. Puskas

September 22, 2018

Presentation TCT 2018

PCI for MVD: Is Complete Revascularization the Missing Link? Anatomic or Functional?

Presenter: Antonio Colombo, Jeffrey W. Moses, William F. Fearon

September 22, 2018

Presentation TCT 2018

How Much Has PCI (and CABG) Improved in MVD and LMD: Insights From SYNTAX II and SYNTAX-EXCEL Comparative Analyses

Presenter: Antonio Colombo, Jeffrey W. Moses, Patrick W. Serruys

September 22, 2018

Presentation TCT 2018

Mortality and Stroke Outcomes of PCI vs CABG in MVD and LMD With and Without Diabetes

Presenter: Antonio Colombo, Jeffrey W. Moses, Stuart J. Head

September 22, 2018

Presentation TCT 2018

Defining What Constitutes a Clinically Relevant Peri-Procedural MI: Analysis in > 17,000 Patients

Presenter: Antonio Colombo, Jeffrey W. Moses, Jung-Min Ahn

September 22, 2018

Presentation TCT 2018

TCT-8: Fate Of Deferred Lesions Using State-Of-Art Percutaneous Coronary Revascularization In Patients With De Novo Three Vessel Disease: Lesion Level Analysis At 2 Years Of The SYNTAX II Study

Presenter: Steven R. Bailey, Patrick W. Serruys, Norihiro Kogame

September 22, 2018

Presentation TCT 2018

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Presenter: David J. Cohen, Sunil V. Rao, David J. Maron

September 22, 2018

Presentation TCT 2018

Three-year Outcomes of Surgical Vs. Endovascular Revascularization for Critical Limb Ischemia: The SPINACH Study

Presenter: Osamu Iida, Shigeru Saito

September 21, 2018

Presentation TCT 2018

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

Presenter: Alexandre Abizaid, Didier Carrié, Ariel Roguin

September 21, 2018

Presentation TCT 2018

TCT-90: Clinical Outcomes Three Year After Revascularization With a Biodegradable Polymer Ultra-thin Strut Sirolimus-Eluting Stent and a Biodegradable Polymer Biolimus-eluting Stent. From the SORT OUT VII Trial

Presenter: Alexandre Abizaid, Didier Carrié, Julia Ellert

September 21, 2018

Advertisement

DANCE: Two-Year Outcomes of Adventitial Dexamethasone Delivery During Femoropopliteal Revascularization

CHIP in The Diabetic Patient: Special Considerations

Case #8: A Case of Revascularization Planning by FFRCT (From SYNTAX III)

Complete Revascularization is the Missing Link to Improve Diabetic PCI Outcomes

When is PCI a Valid Alternative To Only Medical Therapy or CABG in the Diabetic Patient?

Medical Therapy for Whom and When: What is the Ceiling of Medical Therapy?

Comprehensive CV Risk Reduction Strategy in Diabetics

Is It Time to Move Beyond Angiography for Procedural Planning? DECISION

Is It Time to Move Beyond Angiography for Procedural Planning? SYNTAX III

MVD Case Presentation With Heart Team Discussion, Case Introduction

Hybrid Revascularization as an Alternative to PCI or CABG

PCI for MVD: Is Complete Revascularization the Missing Link? Anatomic or Functional?

How Much Has PCI (and CABG) Improved in MVD and LMD: Insights From SYNTAX II and SYNTAX-EXCEL Comparative Analyses

Mortality and Stroke Outcomes of PCI vs CABG in MVD and LMD With and Without Diabetes

Defining What Constitutes a Clinically Relevant Peri-Procedural MI: Analysis in > 17,000 Patients

TCT-8: Fate Of Deferred Lesions Using State-Of-Art Percutaneous Coronary Revascularization In Patients With De Novo Three Vessel Disease: Lesion Level Analysis At 2 Years Of The SYNTAX II Study

Optimal Medical Therapy With and Without Coronary Revascularization: Which Drugs Matter? Symptoms, Ischemia, or Prognosis? And Magnitude of Impact

Three-year Outcomes of Surgical Vs. Endovascular Revascularization for Critical Limb Ischemia: The SPINACH Study

TCT-91: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents in Patients Undergoing Coronary Revascularization (BIOFLOW V): Acute Coronary Syndrome Subgroup Analysis

TCT-90: Clinical Outcomes Three Year After Revascularization With a Biodegradable Polymer Ultra-thin Strut Sirolimus-Eluting Stent and a Biodegradable Polymer Biolimus-eluting Stent. From the SORT OUT VII Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content